Anoro Ellipta

Chemical Nameumeclidinium and vilanterol
Dosage FormInhalation (oral; 62.5 mcg umeclidinium and 25 mcg vilanterol)
Drug ClassAnticholinergics
SystemRespiratory
CompanyGlaxoSmithKline
Approval Year2013

Indication

  • Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Last updated on 6/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Anoro Ellipta (umeclidinium and vilanterol) Prescribing Information.2020GlaxoSmithKline, Research Triangle Park, NC